Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Nvidia will help Recursion build a massive supercomputer. This will be used its for AI-driven drug discovery efforts. It may be the first of several moves to empower its platform. With the help of its ...

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference ...

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. SALT LAKE CITY, May ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...